Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of Parkinson's disease. In well-established pre-clinical models of PD, ITI-002 was shown to restore normal motor function when given in combination with L-DOPA; ITI-002 increased the effectiveness of a sub-threshold and a sub-maximal dose of L-DOPA when the compounds were co-administered in unilaterally 6-hydroxy dopamine-lesioned or reserpine-treated mice. This combination resulted in a full restoration of the affected limb use and a re-establishment of normal mobility. ITI-002 also reversed the akinesia and catalepsy induced by the dopamine receptor antagonist haloperidol. In other pre-clinical models, ITI-002 was shown to improve cognitive performance and to increase daytime wakefulness without causing psychomotor stimulation.

"We are pleased to have demonstrated the ability of ITI-002 to improve motor and non-motor behaviors in pre-clinical models relevant to Parkinson's disease. These data suggest ITI-002 may be useful in prolonging the effectiveness and lowering the doses of dopamine replacement therapies, thereby providing for full restoration of motor function without causing troubling side effects in patients with Parkinson's Disease," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "Since ITI-002 acts by enhancing intra-cellular dopamine signaling, ITI-002 also may be useful as a stand-alone treatment early in this disease when residual dopamine is still present.  In addition, patients with Parkinson's disease often suffer co-mor
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... Research and Markets has announced the addition ... In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to ... The global companion diagnostics market is expected to grow ... Factors such as rising need for personalized medicine in ... pharmaceutical industry, support from regulatory authorities, and emerging technologies ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that it ... exchange for 6,634 shares of CTI,s Series A, B ... interest of all,series of CTI,s Convertible Preferred Stock. Each ... 7,143 shares of CTI,s common stock, at a,conversion price ...
... $65.0 MillionRICHMOND, Calif., Feb. 4 Sangamo BioSciences, Inc. (Nasdaq: ... year 2008 financial results and accomplishments and provided an outlook ... Sangamo reported a consolidated net loss of $2.6 million, or ... million, or $0.17 per share, for the same period in ...
... Specialty Pharmacy is,pleased to announce two new "Navigator" ... DSP launched both a Hemophilia and IVIG,Navigator Program. ... as National,Sales Manager for both programs. Reed is ... over 18 years of pharmaceutical sales experience. Most ...
Cached Biology Technology:Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 10Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study ... control leg movements with a National Science Foundation ... four-year project. , Ari Berkowitz, professor in the ... Sciences, will focus on the differences between the ... understand what neurotransmitters they use and what connections ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... brain that controls insulin responses has been shown to ... evidence that the disease can be treated in its ... Rhode Island Hospital and Brown Medical School. , ... prevent several components of neurodegeneration and preserve learning and ...
... known that animals use song as a way of attracting ... unusual way of scaring off predators ?by singing to them. ... that wild gibbons in Thailand have developed a unique song ... survival, the gibbons appear to use the song not just ...
... 21 September, 2006 - Elsevier is delighted to ... the journal Vaccine: HPV Vaccines and Screening in ... provides a comprehensive and invaluable update for paediatricians, ... major donor institutions worldwide. , With the arrival ...
Cached Biology News:Insulin receptor stops progression of Alzheimer's disease 2Insulin receptor stops progression of Alzheimer's disease 3Singing for survival 2Singing for survival 3
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... and 2.0 mL samples for freezing point determinations. Includes built-in printer, keypad, ... with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: